Han Nayoung, Kim Hannah, Min Soo Kee, Paek Sun-Ha, Park Chul-Kee, Choi Seung-Hong, Chae U-Ri, Park Sung-Hye
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
J Pathol Transl Med. 2016 Mar;50(2):113-21. doi: 10.4132/jptm.2015.10.30. Epub 2015 Dec 14.
The term solitary fibrous tumor (SFT) is preferred over meningeal hemangiopericytoma (HPC), because NAB2-STAT6 gene fusion has been observed in both intracranial and extracranial HPCs. HPCs are now considered cellular variants of SFTs.
This study analyzes 19 patients with STAT6-confirmed SFTs, who were followed for over 11 years in a single institution. Ten patients (10/19, 56.2%) had extracranial metastases (metastatic group), while the remainder (9/19) did not (non-metastatic group). These two groups were compared clinicopathologically.
In the metastatic group, the primary metastatic sites were the lungs (n = 6), bone (n = 4), and liver (n = 3). There was a mean lag time of 14.2 years between the diagnosis of the initial meningeal tumor to that of systemic metastasis. The median age at initial tumor onset was 37.1 years in the metastatic group and 52.5 in the non-metastatic group. The 10-year survival rates of the metastatic- and non-metastatic groups were 100% and 33%, respectively. The significant prognostic factors for poor outcomes on univariate analysis included advanced age (≥45 years) and large initial tumor size (≥5 cm). In contrast, the patients with higher tumor grade, high mitotic rate (≥5/10 high-power fields), high Ki-67 index (≥5%), and the presence of necrosis or CD34 positivity showed tendency of poor prognosis but these parameters were not statistically significant poor prognostic markers.
Among patients with SFTs, younger patients (<45 years) experienced longer survival times and paradoxically had more frequent extracranial metastases after long latent periods than did older patients. Therefore, young patients with SFTs require careful surveillance and follow-up for early detection of systemic metastases.
孤立性纤维瘤(SFT)这一术语比脑膜血管外皮细胞瘤(HPC)更受青睐,因为在颅内和颅外HPC中均观察到NAB2 - STAT6基因融合。HPC现在被认为是SFT的细胞变体。
本研究分析了19例经STAT6确诊的SFT患者,这些患者在单一机构接受了超过11年的随访。10例患者(10/19,56.2%)发生颅外转移(转移组),其余9例(9/19)未发生转移(非转移组)。对这两组进行临床病理比较。
在转移组中,主要转移部位为肺(n = 6)、骨(n = 4)和肝(n = 3)。从最初的脑膜肿瘤诊断到全身转移诊断的平均间隔时间为14.2年。转移组初始肿瘤发病的中位年龄为37.1岁,非转移组为52.5岁。转移组和非转移组的10年生存率分别为100%和33%。单因素分析显示,预后不良的显著预测因素包括高龄(≥45岁)和初始肿瘤体积大(≥5 cm)。相比之下,肿瘤分级高、有丝分裂率高(≥5/10高倍视野)、Ki-67指数高(≥5%)以及存在坏死或CD34阳性的患者显示出预后不良的倾向,但这些参数并非具有统计学意义的不良预后标志物。
在SFT患者中,年轻患者(<45岁)的生存时间更长,而且与老年患者相比,在较长的潜伏期后颅外转移更为频繁。因此,SFT年轻患者需要仔细监测和随访,以便早期发现全身转移。